文献速递前列腺癌

前列腺近距离放疗后长期泌尿症状的影响因素

Factors influencing long-term urinary symptoms after prostate brachytherapy.
PubMed 文献 · BJU Int · 2018-05-31

本研究纳入1842例接受永久性种子植入的前列腺癌患者,其中1110例初始AUASS为0-7分。中位随访9.4年发现,初始症状轻微者10年和15年无症状恶化生存率分别为72.9%和39.1%。EBRT推量、放疗剂量>200 Gy2、高血压和饮酒是症状加重的显著危险因素。

要点

  • 初始AUASS轻微者放疗后长期仍有相当比例出现症状加重。
  • EBRT推量、高放疗剂量、高血压和饮酒增加症状恶化风险。
  • 需对接受近距离放疗的前列腺癌患者长期随访泌尿症状。

核心结论

  • 初始AUASS低的前列腺近距离放疗患者长期随访中仍有相当数量出现泌尿症状加重。
  • EBRT推量、放疗剂量>200 Gy2、高血压和饮酒是AUASS升高的危险因素。

研究设计与样本

  • 回顾性分析1842例接受永久性种子植入的前列腺癌患者,随访至少5年(平均9.4年)。
  • 其中1110例(60.3%)初始AUASS为0-7分,接受单纯近距离放疗(n=491)或联合新辅助激素治疗和/或外照射放疗(n=619)。
  • 中位前列腺体积37 mL,前瞻性收集合并症数据。

主要发现

  • 初始症状轻微组AUASS从3.6升至7.3(P<0.001),中度组从11.6降至11.3(P=0.426),重度组从24.1降至16.9(P<0.001)。
  • 初始症状轻微者10年和15年无症状恶化生存率分别为72.9%和39.1%。
  • Cox风险比显著的因素包括EBRT推量(HR 1.45,P=0.004)、放疗剂量>200 Gy2(HR 1.25,P=0.024)、高血压(HR 1.37,P=0.006)和饮酒(HR 1.46,P=0.001)。

临床怎么用

  • 对初始症状轻微的前列腺癌患者行近距离放疗前,应评估高血压和饮酒等可干预因素。
  • 选择联合EBRT或较高放疗剂量时需权衡长期泌尿症状加重风险。
  • 治疗后应长期监测AUASS变化,尤其在高危因素患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine which patient and treatment-related factors are associated with increased American Urological Association symptom score (AUASS) in men who presented with minimal symptoms before treatment for prostate cancer by permanent seed implantation. PATIENTS AND METHODS: Of 1842 men with a minimum follow-up of 5 years (mean 9.4), 1110 (60.3%) had an initial AUASS of 0-7 and were treated with brachytherapy (BT) alone (n = 491) or BT with neoadjuvant hormone therapy (NHT) and/or external beam radiation therapy (EBRT, n = 619). The median prostate volume was 37 mL. Data were prospectively collected on comorbidities. Initial AUASS was compared to last using a Student's t-test (two-tailed). Freedom from increasing from minimal to moderate or severe symptoms was determined by the Kaplan-Meier method with comparisons by log-rank and Cox hazard rates (HRs). RESULTS: The change from pre-treatment score for the minimal, moderate and severe symptom groups was: 3.6-7.3 (P < 0.001), 11.6-11.3 (P = 0.426), and 24.1-16.9 (P < 0.001). For those with minimal symptoms the 10- and 15-year estimates for freedom from worse symptoms were 72.9% and 39.1%, respectively. Cox HRs were significant for EBRT boost (HR 1.45, P = 0.004), RT dose >200 Gy2 (HR 1.25, P = 0.024), hypertension (HR 1.37, P = 0.006), and alcohol use (HR 1.46, P = 0.001). CONCLUSION: A substantial number of men with initial low AUASS treated by BT experience worsening urinary symptoms with long-term follow-up. Use of EBRT, RT dose, hypertension and alcohol use are risk factors for an increase in urinary symptom score.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Stone NN, Winoker JS, Kaplan SA, et al. Factors influencing long-term urinary symptoms after prostate brachytherapy. BJU Int. 2018. PMID: 29726091. doi:10.1111/bju.14365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。